Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

NCT05315713 : A Phase Ib/II Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

One/TwoPhase One/Two

18+Age Over 18

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy | Blood / Myeloma / LymphomaB-Cell Non Hodgkin Lymphoma,Diffuse Large Cell Lymphoma,Leukaemia,Lymphoma

Trial Overview Read MoreRead more

This phase I/II study is trying to understand how safe and effective treatment with a combination of targeted therapies (mosunetuzumab and tiragolumab), with or without immunotherapy (atezolizumab), is in people with relapsed or refractory diffuse large B-cell lymphoma or follicular lymphoma who have received some prior treatment.
 

This trial is treating patients with diffuse large B-cell lymphoma or follicular lymphoma .

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • You have had treatment, but your cancer has come back.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase Ib/II Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Commercial Sponsor

Hoffmann-La Roche

Summary

This is a non-randomised, open-label trial with two experimental arms. In Experimental Arm 1, participants will receive Mosunetuzumab in Combination with Tiragolumab for at least 8 and up to 17 21-day cycles. Mosunetuzumab will be administered via subcutaneous (SC) injection and Tiragolumab will be administered intravenously (via IV) every 3 weeks. In Experimental Arm 2, participants will receive Mosunetuzumab in Combination with Tiragolumab and Atezolizumab for at least 8 and up to 17 21-day cycles. Mosunetuzumab will be administered via subcutaneous (SC) injection, Tiragolumab will be administered intravenously (via IV) every 3 weeks, and Atezolizumab will be administered via IV every 3 weeks. All participants will receive tocilizumab as needed to manage cytokine release syndrome (CRS) events.

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next